FDA grants Orphan Drug Designation to sotatercept
Orphan Drug Designation has been given to sotatercept for the treatment of patients with pulmonary arterial hypertension.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
